Literature DB >> 21975763

Different strategies for diagnosing gestational diabetes to improve maternal and infant health.

Diane Farrar1, Lelia Duley, Debbie A Lawlor.   

Abstract

BACKGROUND: Gestational diabetes mellitus (GDM) is carbohydrate intolerance resulting in hyperglycaemia with onset or first recognition during pregnancy. If untreated, perinatal morbidity and mortality may be increased. Accurate diagnosis allows appropriate treatment.
OBJECTIVES: To evaluate and compare alternative tests for diagnosis of GDM, in terms of maternal and infant health and use of health service resources. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2011). SELECTION CRITERIA: We included randomised trials if they evaluated tests carried out to diagnose GDM. We excluded studies that used a quasi-random model. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion, trial quality and extracted data. MAIN
RESULTS: We identified five small trials, including 578 women. One trial compared three different methods of delivering glucose: a candy bar (39 women), a 50 g glucose polymer drink (40 women) and a 50 g glucose monomer drink (43 women). We have reported results for this trial as two separate comparisons.75 g oral glucose tolerance test (OGTT) versus a 100 g OGTT (one trial, 248 women): women given the 75 g OGTT had a higher relative risk of being diagnosed with GDM (risk ratio (RR) 2.55, 95% confidence interval (CI) 0.96 to 6.75).This difference was borderline for statistical significance. No other measures of maternal morbidity, or outcome for the baby were reported.Candy bar versus 50 g glucose monomer drink (one trial, 82 women): women receiving the candy bar, rather than glucose monomer, reported fewer side effects (RR 0.50, 95% CI 0.26 to 0.97) and preferred the taste (RR 0.62, 95% CI 0.44 to 0.87). No outcomes were reported for the baby.50 g glucose polymer versus 50 g glucose monomer (three trials, 259 women): mean difference (MD) in gestation at birth was -0.80 weeks (one trial, 100 women; 95% CI -1.69 to 0.09). Side effects were less common with the glucose polymer (one trial 82 women; RR 0.20 95% CI 0.07 to 0.54), with no clear difference in taste acceptability (one trial 83 women; RR 0.96; 95% CI 0.78 to 1.18). Significantly fewer women reported nausea following the 50 g glucose polymer drink compared to the 50 g glucose monomer drink (one trial 66 women; RR 0.29; 95% CI 0.11 to 0.78) and bloatedness (two trials 149 women; RR 0.22; 95% CI 0.08 to 0.60). No other measures of maternal morbidity or outcome for the baby were reported.50 g glucose in food versus 50 g glucose drink (one trial, 30 women): women receiving glucose in their food, rather than as a drink, reported fewer side effects (RR 0.08, 95% CI 0.01 to 0.56). There was no clear difference in number of women requiring further testing (RR 0.14, 95% CI 0.01 to 2.55). No other measures of maternal morbidity or outcome for the baby were reported. AUTHORS'
CONCLUSIONS: There is insufficient evidence to assess which is the best strategy for diagnosing GDM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975763     DOI: 10.1002/14651858.CD007122.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  11 in total

1.  Prediction of gestational diabetes mellitus in the first trimester, comparison of fasting plasma glucose, two-step and one-step methods: a prospective randomized controlled trial.

Authors:  M Ilkin Yeral; A Seval Ozgu-Erdinc; Dilek Uygur; K Doga Seckin; M Fatih Karsli; A Nuri Danisman
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

Review 2.  Different strategies for diagnosing gestational diabetes to improve maternal and infant health.

Authors:  Diane Farrar; Lelia Duley; Therese Dowswell; Debbie A Lawlor
Journal:  Cochrane Database Syst Rev       Date:  2017-08-23

Review 3.  Screening and subsequent management for gestational diabetes for improving maternal and infant health.

Authors:  Joanna Tieu; Philippa Middleton; Andrew J McPhee; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

4.  High-fat diet induced insulin resistance in pregnant rats through pancreatic pax6 signaling pathway.

Authors:  Hao Wu; Yunyun Liu; Hongkun Wang; Xianming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Cost-effectivity analysis of one-step versus two-step screening for gestational diabetes.

Authors:  Sevki Celen; Yasemin Yildiz; Serkan Kahyaoglu; Oktay Kaymak; Murat Ozel; Hakan Timur; Nuri Danisman
Journal:  Eurasian J Med       Date:  2012-08

6.  A two-step screening algorithm including fasting plasma glucose measurement and a risk estimation model is an accurate strategy for detecting gestational diabetes mellitus.

Authors:  C S Göbl; L Bozkurt; P Rivic; G Schernthaner; R Weitgasser; G Pacini; M Mittlböck; D Bancher-Todesca; M Lechleitner; A Kautzky-Willer
Journal:  Diabetologia       Date:  2012-09-22       Impact factor: 10.122

7.  The Predictive Value of Selenium in Diagnosis of Gestational Diabetes: A Nested Case-Control Study.

Authors:  Zeinab Moshfeghy; Khadigeh Bashiri; Mohammad H Dabbaghmanesh; Marzieh Akbarzadeh; Nasrin Asadi; Mehrab Sayadi
Journal:  Int J Gen Med       Date:  2020-02-20

8.  Influence of perinatal factors on thyroid stimulating hormone level in cord blood.

Authors:  Amir-Mohammad Armanian; Mahin Hashemipour; Azadeh Esnaashari; Roya Kelishadi; Ziba Farajzadegan
Journal:  Adv Biomed Res       Date:  2013-06-29

Review 9.  Gestational diabetes mellitus in Africa: a systematic review.

Authors:  Shelley Macaulay; David B Dunger; Shane A Norris
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

10.  A pragmatic controlled trial to prevent childhood obesity within a risk group at maternity and child health-care clinics: results up to six years of age (the VACOPP study).

Authors:  Taina Mustila; Jani Raitanen; Päivi Keskinen; Riitta Luoto
Journal:  BMC Pediatr       Date:  2018-02-27       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.